These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 29141555

  • 1. Antineoplastic Effects of NF-κB Inhibition by DHMEQ (Dehydroxymethylepoxyquinomicin) Alone and in Co-treatment with Radio-and Chemotherapy in Medulloblastoma Cell Lines.
    Ramos PMM, Pezuk JA, Castro-Gamero AM, Oliveira HF, Scrideli CA, Umezawa K, Tone LG.
    Anticancer Agents Med Chem; 2018; 18(4):541-549. PubMed ID: 29141555
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
    Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K.
    Clin Cancer Res; 2005 Feb 01; 11(3):1287-93. PubMed ID: 15709200
    [Abstract] [Full Text] [Related]

  • 4. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
    Lampiasi N, Azzolina A, D'Alessandro N, Umezawa K, McCubrey JA, Montalto G, Cervello M.
    Mol Pharmacol; 2009 Aug 01; 76(2):290-300. PubMed ID: 19461054
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
    Ruan HY, Masuda M, Ito A, Umezawa K, Nakashima T, Yasumatsu R, Kuratomi Y, Yamamoto T, Weinstein IB, Komune S.
    Head Neck; 2006 Feb 01; 28(2):158-65. PubMed ID: 16355386
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ).
    Horiuchi K, Morioka H, Nishimoto K, Suzuki Y, Susa M, Nakayama R, Kawai A, Sonobe H, Takaishi H, Ozaki T, Yabe H, Umezawa K, Toyama Y.
    Cancer Lett; 2008 Dec 18; 272(2):336-44. PubMed ID: 18760530
    [Abstract] [Full Text] [Related]

  • 9. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
    Suzuki K, Aiura K, Matsuda S, Itano O, Takeuchi O, Umezawa K, Kitagawa Y.
    Clin Exp Metastasis; 2013 Apr 18; 30(4):381-92. PubMed ID: 23111540
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Possible role of peritoneal NF-κB in peripheral inflammation and cancer: lessons from the inhibitor DHMEQ.
    Umezawa K.
    Biomed Pharmacother; 2011 Jul 18; 65(4):252-9. PubMed ID: 21723080
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Anti-tumor activity of dehydroxymethylepoxyquinomicin against human oral squamous cell carcinoma cell lines in vitro and in vivo.
    Yasuda A, Kondo S, Nagumo T, Tsukamoto H, Mukudai Y, Umezawa K, Shintani S.
    Oral Oncol; 2011 May 18; 47(5):334-9. PubMed ID: 21459660
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of MMP-2-mediated cellular invasion by NF-κB inhibitor DHMEQ in 3D culture of breast carcinoma MDA-MB-231 cells: A model for early phase of metastasis.
    Ukaji T, Lin Y, Okada S, Umezawa K.
    Biochem Biophys Res Commun; 2017 Mar 25; 485(1):76-81. PubMed ID: 28188787
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation.
    Dabaghmanesh N, Matsubara A, Miyake A, Nakano K, Ishida T, Katano H, Horie R, Umezawa K, Watanabe T.
    Cancer Sci; 2009 Apr 25; 100(4):737-46. PubMed ID: 19469019
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K.
    J Bone Miner Res; 2005 Apr 25; 20(4):653-62. PubMed ID: 15765185
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-κB, on glioblastoma.
    Fukushima T, Kawaguchi M, Yorita K, Tanaka H, Takeshima H, Umezawa K, Kataoka H.
    Neuro Oncol; 2012 Jan 25; 14(1):19-28. PubMed ID: 21968049
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.